Patrick Jordan is CEO of Mycovia Pharmaceuticals and Partner at NovaQuest Capital Management. Mycovia is advancing a novel oral therapy for the treatment of recurrent vulvovaginal candidiasis, which affects 138 million women with significant physical, emotional, and financial consequence. Owing to Mycovia’s progress in addressing a major global health concern, Mycovia was recognized as the 2019 Buzz of BIO for Late Stage Leaders. Mr. Jordan was named 2020 CEO of the Year by Triangle Business Journal.
At NovaQuest, Mr. Jordan brings more than 25 years of healthcare leadership in corporate development, operations, and provider services to structure financing solutions for the biopharmaceutical industry.
Mr. Jordan earned a BA from Duke University; an MA from the University of Durham, UK; and an MBA from the Fuqua School of Business at Duke University.
At NovaQuest, Mr. Jordan brings more than 25 years of healthcare leadership in corporate development, operations, and provider services to structure financing solutions for the biopharmaceutical industry.
Mr. Jordan earned a BA from Duke University; an MA from the University of Durham, UK; and an MBA from the Fuqua School of Business at Duke University.
Speaking In
[Available On-Demand]
At Mycovia, we are passionate about developing novel drugs in areas of unmet medical need, with an…
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
